Millennium Biotech and Provider Services extend deal

21 January 2008

New Jersey-based Millennium Biotechnologies, a wholly-owned subsidiary of the Millennium Biotechnologies Group, says it is set to receive funding of $600,000 from its one-year product development agreement with fellow US firm Provider Services. Under the terms of the accord, which includes a $20.0 million five-year purchasing deal, the former will focus on the creation of a ready-to-drink nutrition product for patients in long-term care in the latter's facilities.

Mark Mirken, MB's chief operating officer, said that the agreement would allow the firm to employ its extensive clinical experience in cancer and HIV in addressing the nutritional challenges of long-term care. These thoughts were echoed by Provider Services' chief executive, Brian Colleran, who commented that "expanding our relationship with MBI and MBTG by funding the product development...will give us a significant cost savings and market advantage."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight